生产企业：Treeline Biosciences
TLN-254 is an oral small molecule inhibitor of EZH2 developed by Treeline Biosciences. It was in-licensed following Phase 2 evaluation and approval in China, and is currently in Phase 1 clinical trials for the treatment of T-cell lymphoma and aggressive lymphomas, with potential for combination therapy with TLN-121 (a BCL6 degrader).
TLN-254 is an oral small molecule inhibitor of EZH2 developed by Treeline Biosciences. It was in-licensed following Phase 2 evaluation and approval in China, and is currently in Phase 1 clinical trials for the treatment of T-cell lymphoma and aggressive lymphomas, with potential for combination therapy with TLN-121 (a BCL6 degrader).
TLN-254 is being evaluated in Phase 1 clinical trials for the treatment of T-cell lymphoma and aggressive lymphomas, with potential for combination therapy with TLN-121.
共 2 项相关疾病
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
